Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.

Manufactures pharmaceuticals

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Hanmi Science Co., Ltd. engages in the management of its subsidiaries. It is mainly engaged in the manufacturing and selling of pharmaceutical ingredients and intermediates. The company was founded on June 15,1973 and is headquartered in Hwaseong-si, South Korea.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Manufactures pharmaceuticals for cardiovascular treatment, central nervous system, internal medicine drugs and oncology treatment

Manufactures and sells pharmaceuticals

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

ratiopharm GmbH engages in the production and distribution of generic drugs and pharmaceutical products. It offers pain relievers, nasal sprays, bronchial drops, as well as medicines for treating high blood pressure, cancer, pulmonary arterial hypertension, human immunodeficiency virus infection and acquired immune deficiency syndrome. The company was founded in 1973 and is headquartered in Ulm, Germany.

Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the manufacture, research and development, and marketing of pharmaceutical drugs. Its products include valsartan, irbesartan, candesartan cilexetil, olmesartan medoxomil, piperaquine phosphate, voriconazole, lansoprazole, rabeprazole sodium, dasatinib, and gefitinib. The company was founded on December 30, 1999 and is headquartered in Zhuhai, China.

Ohara Pharmaceutical Co., Ltd. manufactures, distributes, imports, and exports pharmaceuticals and related food additives. It also specializes in orphan drugs for Leukemia, Leukocytpenia, stem cell transplantation, and Parkinson's disease. The company was founded on November 5, 1964 and is headquartered in Koka, Japan.

Alembic Ltd. engages in the pharmaceutical and real estate business. It operates through the Active Pharmaceutical Ingredient (API) and Real Estate segments. The API segment manufactures and markets fermentation and chemistry based API. The Real Estate segment involves the construction of residential and commercial real estate projects, project management, and marketing consultancy. The company was founded on July 30, 1907 and is headquartered in Vadodara, India.

HANALL BIOPHARMA Co., Ltd. engages in the manufacture and sale of synthetic drug and biopharmaceuticals. It offers products such as medicine for digestion, high blood pressure, cerebrovascular disease, myocardial infarction, anti-diabetics, antibiotics, gastrointestinal, bone structure, erectile dysfunction, hives, and other pharmaceutical products. The company was founded by Byeong-Tae Kim on November 20, 1973 and is headquartered in Daejeon, South Korea.

Lek Pharmaceuticals dd, a subsidiary of Novartis AG, is a company headquartered in Ljubljana, Slovenia, that develops, manufactures and markets drugs and pharmaceutical products. Robert Ljoljo is the CEO, in this role since 2019. On November 21, 2002 Novartis AG acquired Lek Pharmaceuticals dd for $689.24 million.

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Teva Pharmaceuticals USA, Inc. engages in the manufacturing and marketing of generic pharmaceuticals. The firm also provides medical affairs, quality plus safety and trade partner services. The company was founded in 1985 and is headquartered in Parsippany, NJ.

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Ark Therapeutics Ltd. engaged in manufacturing of pharmaceutical products. The company was founded on April 30, 2018 and is headquartered in London, the United Kingdom.

AstraZeneca is an innovation-driven biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines that make a meaningful difference in healthcare. AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicines that are innovative, effective, and which offer added benefits such as reduced side effects or better ways of taking the treatment. AstraZeneca focuses on getting the best from every medicine they make by exploring all the ways it can be used or improved. AstraZeneca was established on April 6, 1999, in Cambridgeshire, United Kingdom.